Kenvue Q2 Sales Miss, Margins Squeezed; Guidance Pulled Ahead of Merger
KVUE sits 37% above its 52-week low of $14.02.
Summary
Kenvue's Q2 sales of $3.96B slightly missed the $3.97B consensus, while adjusted EPS rose 7% to $0.31. Gross and operating margins contracted under inflation, tariffs, and higher brand spending. The company suspended forward guidance due to the pending Kimberly-Clark acquisition, expected to close in Q4 2026. This follows the July FDA approvals for Tylenol with Naproxen and the revived Tylenol litigation, adding complexity to the consumer health story. The guidance withdrawal removes a key visibility anchor for investors as the merger approaches.
At the time of this announcement, KVUE was trading at $19.15 on NYSE in the Trade & Services sector, with a market capitalization of approximately $37.8B. The 52-week trading range was $14.02 to $22.22. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.